Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
製藥和醫療保健在改期後的大麻方面會有競爭優勢嗎？數據分析專家權衡
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
BDSA首席執行官羅伊·賓厄姆預計，美國大麻市場將大幅增長，預計到2028年銷售額將達到近460億美元。
This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says.
這種增長將主要由成人用途市場的擴大以及醫療和娛樂等新的許可和監管市場的採用來推動。賓厄姆說，推動這種激增的主要州包括紐約、新澤西州，可能還有佛羅里達州和俄亥俄州。
Influence Of DEA Rescheduling
緝毒局改期的影響
Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he...
在緝毒局決定將大麻重新歸類爲附表三之後，賓厄姆預測這將爲醫學研究和...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。